Manufacturer of Controlled Substances; Notice of Application, 65544 [E6-18844]
Download as PDF
<![CDATA[
cprice-sewell on PRODPC62 with NOTICES
65544
Federal Register / Vol. 71, No. 216 / Wednesday, November 8, 2006 / Notices
Public Hearing: A public hearing in
connection with this first investigation
and report will be held at the U.S.
International Trade Commission
Building, 500 E Street, SW.,
Washington, DC beginning at 9:30 a.m.
on March 8, 2007. Requests to appear at
the public hearing should be filed with
the Secretary, no later than 5:15 p.m.,
February 22, 2007, in accordance with
the requirements in the ‘‘Submissions’’
section below.
Written Submissions: In lieu of or in
addition to participating in the hearing,
interested parties are invited to submit
written statements or briefs concerning
this investigation. All written
submissions, including requests to
appear at the hearing, statements, and
briefs, should be addressed to the
Secretary, United States International
Trade Commission, 500 E Street, SW.,
Washington, DC 20436. Any pre-hearing
briefs or statements should be filed not
later than 5:15 p.m., February 22, 2007;
the deadline for filing post-hearing
briefs or statements is 5:15 p.m., March
22, 2007. All written submissions must
conform with the provisions of section
201.8 of the Commission’s Rules of
Practice and Procedure (19 CFR 201.8).
Section 201.8 requires that a signed
original (or a copy so designated) and
fourteen (14) copies of each document
be filed. In the event that confidential
treatment of a document is requested, at
least four (4) additional copies must be
filed, in which the confidential
information must be deleted (see the
following paragraph for further
information regarding confidential
business information). The
Commission’s rules do not authorize
filing submissions with the Secretary by
facsimile or electronic means, except to
the extent permitted by rule section
201.8 (19 CFR 201.8) (see Handbook for
Electronic Filing Procedures, ftp://
ftp.usitc.gov/pub/reports/
electronic_filing_handbook.pdf).
Persons with questions regarding
electronic filing should contact the
Secretary (202–205–2000 or
edis@usitc.gov).
Any submissions that contain
confidential business information must
also conform with the requirements of
section 201.6 of the Commission’s Rules
of Practice and Procedure (19 CFR
201.6). Section 201.6 of the rules require
that the cover of the document and the
individual pages be clearly marked as to
whether they are the ‘‘confidential’’ or
‘‘non-confidential’’ version, and that the
confidential business information be
clearly identified by means of brackets.
All written submissions, except for
confidential business information, will
VerDate Aug<31>2005
15:11 Nov 07, 2006
Jkt 211001
be made available for inspection by
interested parties.
In its request letter, the Committee
stated that it intends to make the
Commission’s report available to the
public in its entirety, and asked that the
Commission not include any
confidential business information or
national security classified information
in the reports that the Commission
sends to the Committee. Any
confidential business information
received by the Commission in this
investigation and used in preparing this
report will not be published in a manner
that would reveal the operations of the
firm supplying the information.
General information concerning the
Commission may also be obtained at
https://www.usitc.gov. The public record
for this investigation may be viewed on
the Commission’s electronic docket
(EDIS) at https://www.usitc.gov/
secretary/edis.htm. Hearing-impaired
individuals are advised that information
on this matter can be obtained by
contacting our TDD terminal on (202)
205–1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202–205–2000.
Issued: November 2, 2006.
By order of the Commission.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E6–18846 Filed 11–7–06; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on August 21, 2006
and August 24, 2006, Johnson Matthey,
Inc., Custom Pharmaceuticals
Department, 2003 Nolte Drive, West
Deptford, New Jersey 08066, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
Drug
Schedule
Nabilone (7379) ............................
Noroxymorphone (9668) ..............
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sales to its customers.
PO 00000
Frm 00094
Fmt 4703
Sfmt 4703
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than January 8, 2007.
Dated: November 2, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–18844 Filed 11–7–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Foreign Claims Settlement
Commission
[F.C.S.C. Meeting Notice No. 9–06]
Sunshine Act Meeting Notice
The Foreign Claims Settlement
Commission, pursuant to its regulations
(45 CFR Part 504) and the Government
in the Sunshine Act (5 U.S.C. 552b),
hereby gives notice in regard to the
scheduling of meetings for the
transaction of Commission business and
other matters specified, as follows:
Thursday, November 16,
2006, at 10 a.m.
DATE AND TIME:
SUBJECT MATTER: Issuance of Amended
Proposed Decisions and Amended Final
Decisions in claims against Albania.
Open.
All meetings are held at the Foreign
claims Settlement Commission, 600 E
Street, NW., Washington, DC. Requests
for information, or advance notices of
intention to observe an open meeting,
may be directed to: Administrative
Officer, Foreign Claims Settlement
Commission, 600 E Street, NW., Room
6002, Washington, DC 20579.
Telephone: (202) 616–6988.
STATUS:
Mauricio J. Tamargo,
Chairman.
[FR Doc. 06–9160 Filed 11–6–06; 3:48 pm]
BILLING CODE 4410–01–P
E:\FR\FM\08NON1.SGM
08NON1
]]>Agencies
[Federal Register Volume 71, Number 216 (Wednesday, November 8, 2006)]
[Notices]
[Page 65544]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-18844]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on August 21, 2006 and August
24, 2006, Johnson Matthey, Inc., Custom Pharmaceuticals Department,
2003 Nolte Drive, West Deptford, New Jersey 08066, made application by
letter to the Drug Enforcement Administration (DEA) to be registered as
a bulk manufacturer of the basic classes of controlled substances
listed in schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Nabilone (7379)............................ II
Noroxymorphone (9668)...................... II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for sales to its customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such substances may file comments or objections
to the issuance of the proposed registration pursuant to 21 CFR
1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative/ODL; or any being sent via express mail should be sent
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must
be filed no later than January 8, 2007.
Dated: November 2, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-18844 Filed 11-7-06; 8:45 am]
BILLING CODE 4410-09-P
